Report Subject - Market Access - Page 1

Learn More The Future of Key Account Management in Pharma

Are you ready for fundamental disruption to key account management practice? While the Key Account Management (KAM) role will continue to prioritise the development of long-term, sustainable partnerships between...

Compare
Learn More Benchmarking Key Account Management Capabilities (2019)

What factors determine a Key Account Manager (KAM) team's size and structure? At what stage in a product's lifecycle are KAMs assigned and how many brands should a typical KAM support? What personal attributes and...

Compare
Learn More Real-World Data Capabilities: Benchmarking Pharma Companies (2019)

Are you fully and efficiently exploiting real-world data across your business? The impact of real-world data (RWD) is growing but few companies are fully exploiting its potential across all clinical and commercial areas...

Compare
Learn More Charting MSL Activity and Performance 2019

Understand which MSL activities are seen as being most important in the US and Western Europe Benchmark your own MSL programmes and identify new ways to improve performance Identify the most widely-used performance...

Compare
Learn More Trends in KOL Experience Management

How well does your MSL KOL engagement activity compare to competitors? What tools are being used today to measure engagement with KOLs? How often are KOLs surveyed regarding satisfaction levels? Which metrics are...

Compare
Learn More Indication-level Pricing: Payer Insights

Can pharma persuade payers of the benefits of indication-level pricing? Advocates argue that indication-level pricing can bring new products on stream and results in wider patient access to new therapies. That's a good...

Compare
Learn More KAM Metrics: Measuring Success (2019)

Secure a successful future for your KAM teams by proving their true value KAM teams are still evolving but they're also concerned about their future. They need appropriate measures to demonstrate their true value...

Compare
Learn More MSL Teams: Field Force size and structure (2019)

What factors determine the optimum MSL field-based team size and structure? How many brands should MSL field-based teams represent and what constitutes an acceptable territory? What educational background and...

Compare
Learn More Real World Data and Evidence: Payer Insights

Payers have great expectations for real world data. Is pharma meeting them? It's sink or swim time. Advancements in drug data collection methodologies and deeper understanding of what can be achieved has finally opened...

Compare
Learn More Review of Influence: The Institute for Clinical and Economic Review (ICER)

As the Institute for Clinical and Economic Review's (ICER) influence on payer behaviour and health policy grows, how should pharma respond? The ICER's novel and inclusive work on the value of drugs, using its own value...

Compare
Learn More Trends in Pharma-Patient Engagement

Exactly how is Pharma organising and benefitting from its patient engagement strategy? How are patient engagement teams structured and resourced? When do teams engage with patients and what are the main...

Compare
Learn More Trends in Digital Pharma Marketing

What are the trends and developments that will drive pharma's digital marketing initiatives? What are the trends that are shaping digital pharma marketing? How will increased investment be used to drive the digital...

Compare
Learn More Innovative drugs: Mapping the Pricing and Reimbursement Landscape

Health Technology Assessment (HTA) reviews are shaping the competitive landscape for innovative drugs in non-US markets. Between January 2016 and June 2018, 95 innovative medicines were approved in the US–but only...

Compare
Learn More Market Access Team Structure and Function – Industry Survey (2019)

How are market access teams developing to meet evolving stakeholder demands? What are the trends that are defining market access skills? Which core competencies should teams be developing for the future? What market...

Compare
Learn More Charting Real World Data and Evidence - Activity and Capabilities (2018)

How do Real World Data (RWD) and Real World Evidence (RWE) professionals see their critical role developing? Which teams are using RWD/RWE, where is it providing most value and how might this change over the next 2...

Compare
Learn More The MSL Technology Survey (2018)

How is technology changing the face of MSL/KOL interaction and which technologies are set to take a greater role is this critical relationship? Which technologies are being employed to identify KOLs? What technology...

Compare
Learn More HTA in Europe: Key Success Factors for Positive HTA Recommendations

Is there a magic formula for achieving HTA approvals in Europe? Securing a HTA approval in Europe makes sound commercial sense but it's proving easier said than done. Negative or restrictive HTA recommendations are on...

Compare
Learn More Paying for Digital Health: Payer Insights

Payers love digital technologies that reduce health costs and deliver patient benefit–but who should pick up the tab? Digital technology is revolutionising healthcare from advanced electronic medical records and...

Compare
Learn More Biosimilars: US Payer Perspectives (2018)

US payers eye European biologics market with envy Biosimilars may be a roaring success in Europe but the picture in the US couldn't be more different. Once hailed as a solution to stem the tide of soaring drug spending,...

Compare
Learn More Benchmarking Pharma’s MSL Capabilities

Are you convinced your MSL teams are keeping up with evolving market practice? The best medical science liaison (MSL) teams have made significant changes to adapt to a whole new world. The pharma companies getting the...

Compare

Browse by

FirstWord Market Access Reports